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Abstract
Post-angioplasty, patient adherence to recommended antiplatelet therapy decreased when newer, more
expensive drugs were introduced. From 2008-2016, as the use of newer agents increased, the proportion of
patients not filling any antiplatelet prescription within 30 days of discharge increased from 6.4% to 19.1%. In
the subsequent 12 months, the newer drugs were associated with higher patient costs and lower adherence to
recommended therapy.
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THE QUESTION
Percutaneous coronary intervention (PCI), or angioplasty, is a 
procedure that reopens blocked coronary arteries in patients with acute 
coronary syndrome. Almost all patients receive a stent, a small metal 
mesh that help keep the artery open. After PCI, patients must take 
antiplatelet therapy for 6-12 months to help prevent blood clots from 
forming, thereby reducing the likelihood of stroke, myocardial infarction, 
or cardiovascular deaths.
Current guidelines recommend two newer, more expensive antiplatelet 
agents—prasugrel and ticagrelor—over an earlier one, clopidogrel.  
Although there are some clinical trade-offs, the newer agents have been 
shown to be more efficacious in preventing serious adverse outcomes.
To be effective, drugs must be used. Adherence has been a problem in 
antiplatelet therapy, with 12-month adherence rates varying from 30% 
to 90%. Did the introduction of newer P2Y12 inhibitors affect adherence 
to antiplatelet therapy?  The authors used a large commercial claims 
database to assess use, trends, costs, and adherence rates for all three 
agents from 2008-2016, an interval that spans FDA approval for 
prasugrel (July 2009) and ticagrelor (July 2011). 
THE FINDINGS
In this study of 55,340 patients who underwent PCI from 2008 to 2016, the 
proportion of patients filling a prescription for clopidogrel within 30 days 
of discharge decreased from 93.6% to 44%, while the proportion filling a 
prescription for prasugrel or ticagrelor increased from zero to 36.9%  
(Figure 1).  During the same period, the proportion of patients who did not 
fill any P2Y12 inhibitor prescription within 30 days increased from 6.4% to 
19.1%.  Patients not filling a prescription were less likely to be white, less likely 
to be male, and more likely to reside in the Southern United States. 
Patients filling a prescription for clopidogrel had an average copayment of 
$21.40 for a 30-day supply, compared to $48.10 for prasugrel and $48.60 
for ticagrelor. Patients who did not fill a P2Y12 inhibitor prescription within 
30 days of discharge more frequently lived in areas with less household 
net worth.  The proportion of non-adherent patients from the lowest net 
worth communities increased from 2008 to 2016 (10.8% to 15.7%), while the 
proportion decreased from the highest worth communities (13.6% to 9.8%) 
(Figure 2). 
Nearly 80% of patients received a drug-eluding stent, where antiplatelet 
therapy is recommended for 12 months. In these patients, continuing 
adherence largely mirrored that of the initial fill, with patients less likely to 
continue prescriptions for the newer medications. At six months, patients 
who filled clopidogrel had the medication available 85% of the time, 
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compared to 79% for prasugrel and 76% for ticagrelor. At 12 months, 
these percentages dropped to 76%, 71%, and 68%, respectively. At 12 
months, ticagrelor had the highest average copayments, $557, compared 
to prasugrel ($556) and clopidogrel ($251).
Nonadherence was associated with poorer six-month outcomes, 
included recurrent acute coronary syndrome and hospitalizations for 
bleeding.
THE IMPLICATIONS
One implication of this study is that the introduction of new 
drugs may have exacerbated socioeconomic health disparities. 
Increased prescribing of new, more expensive agents can affect 
health outcomes by worsening adherence among patients with 
low socioeconomic status, thereby putting them at risk for further 
cardiovascular events.
Patients were less likely to fill prescriptions for newer P2Y12 inhibitors, 
and less likely to continue to fill these prescriptions. The newer 
drugs partially replaced a lower-cost generic, resulting in higher 
out-of-pocket costs for patients. The most financially disadvantaged 
patients had higher rates of nonadherence, and nonadherence rates 
among those patients increased from 2008-2016. This suggests that 
increased prescribing of the newer, more expensive P2Y12 inhibitors 
may be contributing to higher rates of nonadherence. 
THE STUDY
The authors used administrative claims data from UnitedHealthcare 
to identify patients aged 18-64 hospitalized for PCI from January 
1, 2008 to December 1, 2016. They identified filled prescriptions for 
a P2Y12 inhibitor from pharmacy claims. They grouped patients by 
type of P2Y12 inhibitor and compared baseline characteristics such as 
demographics, region, and household net worth. They measured the 
proportion of patients filling prescriptions for P2Y12 inhibitors within 
30 days of discharge for each year. 
To assess whether patients continued to fill prescriptions, the 
authors looked at nonadherence in patients receiving drug-eluting 
stents, where P2Y12 inhibitors are indicated for 12 months. They 
measured rates of recurrent acute coronary syndrome and bleeding 
complications for each P2Y12 inhibitor, and compared patients’ out-of-
pocket costs across the agents.
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Figure 2. Community mean household net worth in patients who 
underwent PCI and did not fill any prescription for any P2Y12 inhibitor within 
30 days of discharge.
Figure 1. Percentage of patients who underwent PCI and filled a 
prescription for clopidogrel, prasugrel, and ticagrelor within 30 days of 
discharge, 2008-2016.
